DRTS
Alpha Tau Medical Ltd.
$9.71
-0.63
(-6.09%)
Mkt Cap
910.02M
Volume
229,712
52W Range
2.75-10.8
Sector
Healthcare
Beta
1.12
EPS (TTM)
-0.53
P/E Ratio
-9.36
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (42.63M) | (31.75M) | (29.16M) | (33.76M) | (27.27M) | (8.88M) | (8.46M) |
| EPS | -0.53 | -0.45 | -0.42 | -0.53 | -0.67 | -0.22 | -0.13 |
| Free Cash Flow | (32.76M) | (22.02M) | (24.36M) | (24.78M) | (14.74M) | (11.02M) | (8.20M) |
| FCF / Share | -0.41 | -0.31 | -0.35 | -0.39 | -0.36 | -0.27 | -0.12 |
| Operating CF | (26.68M) | (19.78M) | (17.96M) | (23.88M) | (11.81M) | (7.25M) | (6.91M) |
| Total Assets | 106.58M | 86.20M | 107.39M | 120.15M | 42.22M | 52.99M | 31.56M |
| Total Debt | 13.73M | 12.54M | 13.28M | 5.19M | 53.96M | 53.96M | 0 |
| Cash & Equiv | 15.98M | 13.72M | 12.66M | 5.84M | 23.24M | 15.60M | 1.83M |
| Book Value | 77.10M | 62.67M | 84.47M | 105.66M | (34.78M) | (8.43M) | (193,000) |
| Return on Equity | -0.55 | -0.51 | -0.35 | -0.32 | N/A | N/A | N/A |
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.14M) | (11.69M) | (10.11M) | (8.69M) | (9.48M) | (6.92M) | (7.37M) | (7.98M) | (7.37M) | (4.91M) | (8.69M) | (8.19M) |
| EPS | -0.14 | -0.14 | -0.13 | -0.12 | -0.14 | -0.10 | -0.11 | -0.11 | -0.11 | -0.07 | -0.13 | -0.12 |
| Free Cash Flow | (32.76M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FCF / Share | -0.38 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating CF | (26.68M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 106.58M | 104.69M | 110.95M | 80.93M | 86.20M | 90.73M | 96.05M | 102.44M | 107.39M | 106.74M | 111.21M | 116.05M |
| Total Debt | 13.73M | 13.50M | 13.31M | 12.29M | 12.54M | 12.56M | 12.56M | 12.94M | 13.28M | 6.05M | 6.28M | 6.45M |
| Cash & Equiv | 15.98M | 3.33M | 11.70M | 5.02M | 13.72M | 5.53M | 2.76M | 10.42M | 15.81M | 82,000 | 855,000 | 899,000 |
| Book Value | 77.10M | 77.58M | 86.62M | 56.33M | 62.67M | 69.40M | 74.02M | 79.07M | 84.47M | 89.85M | 92.56M | 99.18M |
| Return on Equity | -0.16 | -0.15 | -0.12 | -0.15 | -0.15 | -0.10 | -0.10 | -0.10 | -0.09 | -0.05 | -0.09 | -0.08 |
DRTS News
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona's Pancreas Institute
Alpha Tau Reports 100% Local Disease Control in Early Pancreatic Cancer Data as Program Gains Momentum (DRTS)
Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab
Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Receives Consensus Rating of “Hold” from Brokerages